Introduction
Toll-like receptors (TLRs) contain a leucine-rich repeat ectodomain which enables the recognition of pathogen-associated molecular patterns . Among the 10 TLRs identified in humans, TLR7 is the least studied. This TLR binds single-stranded viral RNA, it localises to 1 endosomal compartments and is particularly expressed by plasmacytoid dendritic cells (pDCs) . Ligand binding to TLR7 activates human 2 pDCs which respond by producing either pro-inflammatory cytokines or substantial levels of type I IFN and activating specific T cells3 -5
. In addition, we have recently demonstrated that Flu-and TLR7 agonist-activated pDCs express TNF-related apoptosis-inducing ligand (TRAIL). This renders them capable of direct cytotoxic activity towards infected and tumor cells . This has been observed : Stary 6 in vivo
. describe the presence of TRAIL-expressing and IFN-producing pDCs in tumors after topical use of the TLR7 ligand imiquimod in et al Blood 
Materials and methods

Antibodies, Flow cytometry
Surface or intracellular phenotype was determined by flow cytometry on a FACS Canto II (Becton-Dickinson, Mountain View, CA, USA), using specific antibodies, by direct or indirect labelling. The following antibodies were from Immunotech (Beckman Coulter, Marseille, France): PE-conjugated anti-CD40 (mAb89), PE-conjugated anti-CD80 (mAb104) and PE-conjugated goat anti-mouse IgG (H L). PE-conjugated anti-CD123 (9F5) was purchased from Pharmingen (San Diego, CA, USA). PE-conjugated anti-phospho-STAT1 + (4a/pY701-stat1) was from BD (Becton-Dickinson). FITC-conjugated anti-BDCA-2 (AC144) and FITC-conjugated anti-IFN-α (LT27:295) were from Miltenyi Biotec (Paris, France) and purified anti-TRAIL (2E5) from Alexis (Lausen, Switzerland).
Cells
Normal pDCs were isolated from PBMC of healthy volunteers with a BDCA-4 cell isolation kit (Miltenyi Biotec). Their purity, as determined with anti-BDCA-2 and anti-CD123 mAbs, was about 80 ( ). % Figure 1 .A The pDC cell line GEN2.2 was grown in complete medium (RPMI 1640 Glutamax (GibcoBRL, Cergy-Pontoise, France) supplemented with 1 mM sodium pyruvate, 20 g/ml gentamicin, nonessential amino acids) to which 10 heat inactivated Fetal Calf 
Protein extraction and signaling factor analysis
After stimulation of GEN2.2 cells, cytosolic and nuclear fractions were extracted using the protein extraction kit from Active Motif (Rixensart, Belgium). Nuclear extracts were probed for NF B subunits c-Rel, p50, p52, p65 and RelB content using the TransAM NF B κ κ family kit (Active Motif). Whole cell extracts were used for quantification of phospho-STAT1 and phospho-p38MAPK by CBA multiplex (BD Biosciences).
Western-blot analysis
Following activation, GEN2.2 cells were washed in phosphate-buffered saline (PBS), lysed in 100 ml of sample buffer, and heated at 100 C for 5 minutes. Whole-cell extract (20 g) was loaded onto a 12 SDS-polyacrylamide gel. After electrophoresis, proteins were°μ % transferred to a PVDF membrane (BIORAD, Marne la Coquette, France). Non-specific binding sites were blocked with 5 nonfat milk in % PBS Tween20 0.1 . Membranes were then incubated with primary antibodies: anti-phospho-STAT1 (4a/pY701), anti-phospho-STAT2 % (7a/pY) (Pharmingen) and anti-actin (Sigma). Antibody labeling was revealed using horseradish peroxidase (HRP)-conjugated secondary antibodies (Dako, Glostrup, Denmark) and was visualized using enhanced chemiluminescence (ECL, Amersham Life Science, Les Ulis, France).
Immunofluorescence
Twenty one well Teflon printed slides (Immuno-Cell International, Mechelen, Belgium) were coated with 1 g/ml poly-L-lysine μ (Sigma). 10 GEN2.2 cells were added to each well and allowed to adhere for 1 h. Cells were then stimulated for 2 and 3 h with 640 4 UHA/ml UV-formol-inactivated virus strain A/H3N2/Wisconsin/67/05, 1 g/ml CL097 or 5,000 U/ml human recombinant IFNinfluenza μ . After activation, medium was removed, slides were fixed in 20 C methanol for 10 min and dried at room temperature for 1 h. Slides were rehydrated in PBS for 10 min and then incubated with primary antibody anti-IRF7 (H-246, Santa Cruz Biotechnology, San Diego, CA, USA). Antibody labeling was revealed using FITC-conjugated goat anti-rabbit secondary antibody (Pharmingen). Cells were also colored with 1 mg/ml Evans blue (Sigma) before visualization by fluorescence microscopy. ). This result corroborates the type I IFN production profile described above. These data suggest 
Quantitative RT-PCR
IFN-inducible genes are expressed after TLR7 triggering in a type I IFN-independent manner
Secretion of type I IFNs by pDCs leads to the expression of a group of IFN-inducible genes including MxA, CXCL10 and TRAIL18 -
. We next examined whether the differential type I IFN secretion observed after TLR7 triggering could induce differential expression of 4 11 these IFN-inducible genes. IFN-secretion was observed within 4 h after TLR7 stimulation by Flu, whereas no detectable IFN-was α α measured at any time point (up to 24 h) after CL097 activation ( ). Surprisingly, the IFN-inducible genes products were Figure 3 .A nevertheless detected within 4 h after activation by both TLR7 ligands ( ). The expression profiles were identical whatever ). Low-level phosphorylation of STAT2 was also observed ( ). In Figure 5 .B Figure 5 .B these analyses, no variation in total STAT protein quantity was observed (data not shown). These results were further confirmed by flow 
Discussion
Many studies have suggested that the effects triggered by TLR7 ligands as adjuvants in cancer immunotherapy could be attributed to the activation of pDCs and their subsequent type I IFN production , , . In order to understand how agonists for the same receptor lead 5 11 to different activated pDC phenotypes we initiated a study of the signaling pathways induced in pDCs by two different TLR7 ligands. In this article we show that, in contrast to Flu activation, CL097 stimulation of pDCs does not induce production of high levels of IFN-. α However, we were able to demonstrate that both TLR7 ligands led to rapid expression IFN-inducible genes via a type I IFN independent pathway.
The data presented here reveal that Flu and CL097 both trigger human TLR7 but induce differential cytokine production. Using stably shRNA-transfected cells, GENshTLR7, we could demonstrate that human pDC activation by inactivated virus required TLR7, as Influenza had been previously described in a mouse model . Type I IFN production after CL097 activation was found to be null or extremely low 17 compared to the massive amounts of IFN-produced in the presence of Flu. This result corroborated those concerning IRF7 translocation phosphorylation on Tyr-701. This phosphorylation was found to be p38MAPK-dependent in our model, a similar signaling pathway was also described in CpG A-activated pDCs . However, since p38MAPK is a serine kinase, known to phosphorylate STAT1 on Ser-727 , 24 36 this tyrosine phosphorylation of STAT1 must be mediated by an intermediate tyrosine kinase whose activation is dependent on p38MAPK.
Both the Janus kinases (JAK) 1 and 2 and c-Src are able to phosphorylate STAT1 on Tyr-701 , but their activation is generally 23 37 associated with cytokine receptors . In our model, we demonstrated that no soluble factors were involved. Therefore, the intermediate 38 kinase responsible for STAT1 phosphorylation in response to TLR7 stimulation remains to be identified.
Here, we have shown that PI3K is involved in the activation of p38MAPK while other groups have demonstrated its implication in IRF7 translocation , . Moreover, the NF B-dependent expression of CD80 and cytokines production were also impaired in the 25 39 κ presence of LY following TLR7 triggering (data not shown), suggesting that PI3K is a key early signaling factor in the TLR7 pathway.
Altogether, exhaustive characterization of the signaling pathway downstream of TLR7 in pDCs led us to describe the expression of IFN-inducible genes in the absence of cytokine receptor engagement. This originality may confer on pDCs the capacity to respond more rapidly to viral infection, reinforcing their role in the early phases of the immune response. Finally, the work described here may help to define new therapeutic targets which could favor pDC activation in tumor and viral immunotherapy or to dampen it in pDC-driven autoimmunity.
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